FDA's New Policy: Ban on Industry Employees as Advisors, Limits Industry Influence

On April 17, 2025, U.S. FDA Commissioner Dr. Martin A. Makary announced a major policy change prohibiting employees of FDA-regulated companies (such as pharmaceutical firms) from serving as official members of the agency’s advisory committees. This move aims to reduce industry influence on FDA decision-making, eliminate perceived conflicts of interest, and enhance public trust in the agency. The policy is part of a series of reforms introduced since Dr. Makary assumed leadership and reflects the FDA's commitment to greater independence and transparency under HHS Secretary Robert F. Kennedy Jr.’s “radical transparency” directive.

FDA restricts pharmaceutical company employees from serving as official members of FDA advisory committees

Background on FDA Advisory Committees

Role and Function of Advisory Committees

FDA advisory committees are essential to the agency's decision-making, offering independent expert advice on the regulation of drugs, biologics, and medical devices. These committees often deliberate on the safety and effectiveness of unapproved products, among other scientific, technical, or policy matters. Though their recommendations are non-binding, they significantly influence FDA's final decisions.

Under the Federal Advisory Committee Act, these panels consist of external experts who are not full-time federal employees, ensuring diversity of expertise and perspective. Meetings must be announced in the Federal Register and are open to the public, reflecting the FDA’s commitment to transparency.

Committee Composition

There are 33 FDA advisory committees covering drugs, biologics, and medical devices. Each typically includes nine permanent members led by a chairperson, with terms of 1 to 4 years. Members include:

• Scientific Experts: Doctors, researchers, and statisticians offering technical analysis, often with prior industry ties.
• Industry Representatives: As mandated by the 1997 FDA Modernization Act, each committee includes a non-voting industry representative advocating for the industry at large.
• Consumer and Patient Representatives: Provide public and patient perspectives to ensure user needs are considered in decisions.

Committees may also invite temporary members, such as patient advocates, to provide insights on specific issues.

How They Operate

Meetings center around specific questions posed by the FDA, such as whether a drug should be approved or if more research is needed. These sessions are open to the public, including the media and stakeholders. Following discussions, committees may vote. Vote outcomes and minutes are made public to enhance transparency.

Controversies Over Industry Influence

Historical Conflicts of Interest

The FDA has long faced scrutiny over its ties to "Big Pharma" and "Big Food," raising concerns about its impartiality. Lawmakers and advocacy groups have pushed for tighter conflict-of-interest regulations. Despite their role in offering independent advice, committee members' financial links to industry have sparked ongoing controversy. A 2018 Science magazine investigation found that many advisors received large payments from pharmaceutical companies or competitors after product approvals between 2008 and 2014. For example:

• Jonathan Halperin: Received over $200,000 in travel and consulting fees from AstraZeneca and its competitors from 2013–2016.
• Christopher Granger: Received over $63,000 from AstraZeneca and $1.3 million from its competitors during the same period.

FDA advisory committee members' financial ties to industry spark long-running controversy

These payments were often disclosed in academic journals, but the FDA's reliance on self-disclosure without independent verification led to doubts about advisor impartiality.

Inadequate Disclosure and Oversight

Investigations revealed that the FDA failed to effectively detect and disclose advisor conflicts. Eleven high-earning advisors received undisclosed payments from competitors before meetings, while five were paid by drug manufacturers. Freedom of Information Act (FOIA) requests revealed that the FDA could not produce disclosure documents for some advisors, highlighting regulatory gaps.

Crisis of Public Trust

These controversies deepened a public trust crisis. In 2005, Dr. David Graham, then Deputy Director of FDA's Office of Drug Safety, publicly criticized the FDA for prioritizing drug approvals over safety. The conflict-of-interest issues within advisory committees amplified such criticism, prompting the FDA to tighten oversight.

FDA officials publicly criticize FDA for favoring the pharmaceutical industry

Details of the New Policy

Policy Summary

As of April 17, 2025, the new FDA policy bars employees of regulated companies from serving as official (voting) members on advisory committees, except under the following conditions:

• Special Expertise: When required expertise is only available from industry employees.
• Strict Ethics Standards: Participants must comply with rigorous conflict-of-interest disclosure and recusal requirements.

Even when barred from voting roles, industry employees may:

• Attend advisory committee meetings as members of the public and provide input.
• Serve as non-voting representatives when legally required (e.g., under the FDA Modernization Act).

Elevated Role for Patients and Caregivers

The new policy emphasizes increased participation by patients and caregivers, aiming to reflect a broader community voice. This effort seeks to make FDA decisions more patient-centered and responsive to demands for a more representative regulatory process.

Hawkish Reform Meets Dovish Integration

This policy is part of a broader wave of reforms initiated by Commissioner Makary since taking office on April 1, 2025. Other reforms include:

• Phasing Out Animal Testing: On April 10, the FDA announced plans to phase out animal testing for monoclonal antibodies and other drugs in favor of more humane methods like AI (PharmTech Report).
• Leadership Changes: Peter Marks, head of the Center for Biologics Evaluation and Research, resigned on March 28, 2025. Patrizia Cavazzoni, head of the Center for Drug Evaluation and Research, retired in January 2025, marking significant internal changes.

Significance and Potential Impact

Enhanced Committee Independence

The new policy aims to reduce actual and perceived conflicts of interest by restricting voting roles for industry employees. This approach is more aligned with the European Medicines Agency (EMA), which prohibits advisors from having financial ties to industry within three years of a meeting and independently verifies disclosures. The FDA hopes that by strengthening independence, advisory committee recommendations will gain credibility.

Rebuilding Public Trust

Commissioner Makary stated: “Public trust in the medical-industrial complex is at a historic low. We must restore absolute integrity to the process and avoid potential conflicts of interest.” The policy addresses concerns about the FDA’s perceived closeness to industry and may help restore trust.

Potential Challenges

• Loss of Expertise: Industry scientists often have deep expertise in cutting-edge technologies. Excluding them may lower the quality of advice. Though exceptions exist, their frequency and standards are not yet clear.
• Reduced Industry Input: While industry employees can still speak at public meetings, their influence may wane, possibly leading to industry dissatisfaction with FDA processes.

Reference

[1]. https://www.fda.gov/news-events/press-announcements/fda-commissioner-makary-announces-new-policy-individuals-serving-fda-advisory-committees 
[2].https://www.pharmtech.com/view/fda-announces-new-policy-advisory-committee-members 
[3].https://pharmaphorum.com/market-access/new-fda-head-says-no-more-pharma-advisory-committees